A new therapeutic option is now available in Spain to improve glycemic control in adults with type 2 diabetes. This is packaging (marketed under the name of Jardiance), an inhibitor of the Cotransporter 2 of glucose and sodium (SGLT2), which is theThird drug of the Boehringer Ingelheim and Lilly alliance in diabetes that is marketed in Spain.
Pagliflozine is presented in the form of oral tablet, available at 10 mg and 25 mg, in a single daily dose for the treatment of type 2 diabetes in the adult, when diet and exercise alone do not provide sufficient glycemic control.
The new drug is indicated in monotherapy, when metformin is not tolerated and, therefore, is not considered adequate;and combined with other hypoglycemic, including insulin, when they are not enough for blood glucose control.
Up to 78 gr of glucose per day
Although there is a wide range of treatments for the treatment of DM2, 50% of patients do not reach their blood sugar control objectives, due in part to the evolution of the disease.
SGLT2 inhibitors have a different mechanism of action from other oral antidiabetics.They are proteins that play a fundamental role in the resorption of glucose in the kidneys, being responsible for 90% of the reabsorption of glucose back to the blood torrent.In people with type 2 diabetes, there is an overexpression of the SGLT2, which contributes to the increase in blood glucose concentration.
Pagliflozine reduces the ability of the kidneys to reabsorb glucose to the circulatory torrent, directing the elimination of glucose towards urine.Thanks to this mechanism of action, patients treated with this type of drugs can excrete about 78 grams of glucose per day.
